Clinical Trials Browser

Phase 2 × Mouth Neoplasms × Celecoxib × Clear all

NCT06997068 2025-07-14

Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Oral Cavity Cancer in a Rural Midwest United States Population

Phase 2 Recruiting

25 enrolled

Head & Neck

Mouth Neoplasms

NCT04162873 2025-02-12

Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer

Phase 2 Terminated

13 enrolled 36 charts

Head & Neck

Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Paranasal Sinus Neoplasms

NCT00052611 2018-03-29

Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia

Phase 2 Completed

23 enrolled

Head & Neck

Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Nasopharyngeal Neoplasms, Oropharyngeal Neoplasms, Salivary Gland Neoplasms

NCT00101335 2013-07-11

Celecoxib in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia

Phase 2 Completed

Head & NeckOther neoplasm

Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Leukoplakia, Oral, Mouth Neoplasms, Nasopharyngeal Neoplasms, Oropharyngeal Neoplasms, Precancerous Conditions, Tongue Neoplasms

NCT00014404 2013-01-16

Celecoxib in Treating Patients With Precancerous Lesions of the Mouth

Phase 2 Completed

Head & Neck

Head and Neck Neoplasms, Mouth Neoplasms